Medicis Pharmaceutical Corp. (MRX) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $68.38 --0%
Revenue Growth %: +21.2%
Financial Fact:
Loss from discontinued operations, net of income tax benefit: 0
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +21.2%
Financial Fact:
Loss from discontinued operations, net of income tax benefit: 0
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q1 EPS of $0.91, $0.14 better than the analyst estimate of $0.77. Revenue for the quarter came in at $467.3 million versus the consensus estimate of $428.46 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Medline Inc. (MDLN) Reports Q3 EPS of $0.44
- Seres Therapeutics (MCRB) Tops Q3 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
